# AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

> **NCT06196814** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Efficacy

## Interventions

- **DRUG:** PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy

## Key facts

- **NCT ID:** NCT06196814
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196814, "AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06196814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*